Literature DB >> 15995707

Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells.

Giorgio Napolitani1, Andrea Rinaldi, Francesco Bertoni, Federica Sallusto, Antonio Lanzavecchia.   

Abstract

Toll-like receptors (TLRs) sense microbial products and initiate adaptive immune responses by activating dendritic cells (DCs). As pathogens may contain several TLR agonists, we sought to determine whether different TLRs cooperate in DC activation. In human and mouse DCs, TLR3 and TLR4 potently acted in synergy with TLR7, TLR8 and TLR9 in the induction of a selected set of genes. Synergic TLR stimulation increased production of interleukins 12 and 23 and increased the Delta-4/Jagged-1 ratio, leading to DCs with enhanced and sustained T helper type 1-polarizing capacity. Global gene transcriptional analysis showed that TLR synergy 'boosted' only approximately 1% of the transcripts induced by single TLR agonists. These results identify a 'combinatorial code' by which DCs discriminate pathogens and suggest new strategies for promoting T helper type 1 responses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15995707      PMCID: PMC3760217          DOI: 10.1038/ni1223

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  46 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

2.  CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal.

Authors:  O Schulz; A D Edwards; M Schito; J Aliberti; S Manickasingham; A Sher; C Reis e Sousa
Journal:  Immunity       Date:  2000-10       Impact factor: 31.745

3.  Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells.

Authors:  A Langenkamp; M Messi; A Lanzavecchia; F Sallusto
Journal:  Nat Immunol       Date:  2000-10       Impact factor: 25.606

4.  TIRAP: an adapter molecule in the Toll signaling pathway.

Authors:  T Horng; G M Barton; R Medzhitov
Journal:  Nat Immunol       Date:  2001-09       Impact factor: 25.606

5.  Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.

Authors:  B Oppmann; R Lesley; B Blom; J C Timans; Y Xu; B Hunte; F Vega; N Yu; J Wang; K Singh; F Zonin; E Vaisberg; T Churakova; M Liu; D Gorman; J Wagner; S Zurawski; Y Liu; J S Abrams; K W Moore; D Rennick; R de Waal-Malefyt; C Hannum; J F Bazan; R A Kastelein
Journal:  Immunity       Date:  2000-11       Impact factor: 31.745

6.  Lipopolysaccharide and CpG DNA synergize for tumor necrosis factor-alpha production through activation of NF-kappaB.

Authors:  A K Yi; J G Yoon; S C Hong; T W Redford; A M Krieg
Journal:  Int Immunol       Date:  2001-11       Impact factor: 4.823

7.  Synergy and cross-tolerance between toll-like receptor (TLR) 2- and TLR4-mediated signaling pathways.

Authors:  S Sato; F Nomura; T Kawai; O Takeuchi; P F Mühlradt; K Takeda; S Akira
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

8.  Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3.

Authors:  L Alexopoulou; A C Holt; R Medzhitov; R A Flavell
Journal:  Nature       Date:  2001-10-18       Impact factor: 49.962

Review 9.  IL-12 and IL-23: master regulators of innate and adaptive immunity.

Authors:  Claire L Langrish; Brent S McKenzie; Nicholas J Wilson; Rene de Waal Malefyt; Robert A Kastelein; Daniel J Cua
Journal:  Immunol Rev       Date:  2004-12       Impact factor: 12.988

10.  Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens.

Authors:  N Kadowaki; S Ho; S Antonenko; R W Malefyt; R A Kastelein; F Bazan; Y J Liu
Journal:  J Exp Med       Date:  2001-09-17       Impact factor: 14.307

View more
  432 in total

1.  Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients.

Authors:  Michael A Morse; Robert Chapman; John Powderly; Kimberly Blackwell; Tibor Keler; Jennifer Green; Renee Riggs; Li-Zhen He; Venky Ramakrishna; Laura Vitale; Biwei Zhao; Stephen A Butler; Amy Hobeika; Takuya Osada; Thomas Davis; Timothy Clay; H Kim Lyerly
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

2.  Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to that with conventional plasmid DNA vaccine.

Authors:  Maria L Knudsen; Alice Mbewe-Mvula; Maximillian Rosario; Daniel X Johansson; Maria Kakoulidou; Anne Bridgeman; Arturo Reyes-Sandoval; Alfredo Nicosia; Karl Ljungberg; Tomás Hanke; Peter Liljeström
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

3.  Beyond pattern recognition: five immune checkpoints for scaling the microbial threat.

Authors:  J Magarian Blander; Leif E Sander
Journal:  Nat Rev Immunol       Date:  2012-02-24       Impact factor: 53.106

Review 4.  The response of human dendritic cells to co-ligation of pattern-recognition receptors.

Authors:  Tanja Dzopalic; Ivan Rajkovic; Ana Dragicevic; Miodrag Colic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

5.  Off-the-shelf adenoviral-mediated immunotherapy via bicistronic expression of tumor antigen and iMyD88/CD40 adjuvant.

Authors:  Jan Ole Kemnade; Mamatha Seethammagari; Priya Narayanan; Jonathan M Levitt; Alison A McCormick; David M Spencer
Journal:  Mol Ther       Date:  2012-03-20       Impact factor: 11.454

Review 6.  The specialized roles of immature and mature dendritic cells in antigen cross-presentation.

Authors:  Richard A Hopkins; John E Connolly
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

7.  Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responses.

Authors:  Grammatiki Fotaki; Chuan Jin; Mohanraj Ramachandran; Iliana Kyriaki Kerzeli; Alex Karlsson-Parra; Di Yu; Magnus Essand
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

8.  Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma.

Authors:  Kui Shin Voo; Myriam Foglietta; Elena Percivalle; Fuliang Chu; Durga Nattamai; Megan Harline; Seung-Tae Lee; Laura Bover; Heather Y Lin; Veerabhadran Baladandayuthapani; David Delgado; Amber Luong; R Eric Davis; Larry W Kwak; Yong-Jun Liu; Sattva S Neelapu
Journal:  Int J Cancer       Date:  2014-05-12       Impact factor: 7.396

9.  MHC class I and II peptide homology regulates the cellular immune response.

Authors:  Matthew M Halpert; Vanaja Konduri; Dan Liang; Jonathan Vazquez-Perez; Colby J Hofferek; Scott A Weldon; Yunyu Baig; Indira Vedula; Jonathan M Levitt; William K Decker
Journal:  FASEB J       Date:  2020-04-16       Impact factor: 5.191

Review 10.  Plant-derived polysaccharides activate dendritic cell-based anti-cancer immunity.

Authors:  Siambi Kikete; Li Luo; Beitian Jia; Li Wang; Gregory Ondieki; Yuhong Bian
Journal:  Cytotechnology       Date:  2018-03-19       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.